Reengineering Blood Clotting With Bispecific Antibodies
Direct Source Verification:
This story is aggregated from Forbes (forbes.com). Full reporting rights and copyright belong to the primary publisher.
Emicizumab, a bispecific antibody that bridges clotting factors IX and X, restores factor VIII function and prevents bleeding in hemophilia A with infrequent injections.
For complete coverage, context, and related multimedia, visit the original reporting by Forbes via the source link below.
Original Source
https://www.forbes.com/sites/williamhaseltine/2026/10/01/reengineering-blood-clotting-with-bispecific-antibodies/
